Literature DB >> 8818854

Drug interactions with azithromycin and the macrolides: an overview.

M Nahata1.   

Abstract

Evidence interactions between individual macrolides and a number of pharmacologically active compounds that are frequently co-administered to patients with bacterial infections is reviewed. Theophylline is strongly associated with erythromycin interaction; clarithromycin may also interact with this drug. Azithromycin, spiramycin and rokitamycin, however, do not appear to have any effect on theophylline pharmacokinetics. The other therapeutic agents considered are cyclosporin, the antiepileptics, carbamazepine and phenytoin, terfenadine, warfarin, oral contraceptives, agents used in the management of gastritis and peptic ulcer and zidovudine. With the exception of interaction with antacids, there is no evidence that azithromycin, unlike most other macrolides, interacts with any of these agents to produce clinically significant adverse effects. The explanation for this variation appears to be azithromycin's inability to induce and bind to the cytochrome P450 IIIA enzyme system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818854     DOI: 10.1093/jac/37.suppl_c.133

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Re: The new macrolide antibiotics: Use them carefully.

Authors:  M Greenwald
Journal:  Paediatr Child Health       Date:  1998-07       Impact factor: 2.253

Review 2.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

Authors:  R Hafner; J Bethel; M Power; B Landry; M Banach; L Mole; H C Standiford; S Follansbee; P Kumar; R Raasch; D Cohn; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 4.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 5.  Macrolide antibiotics.

Authors:  R C Gordon
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

6.  Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.

Authors:  Byeong-Ho Jeong; Kyeongman Jeon; Hye Yun Park; Seong Mi Moon; Su-Young Kim; Soo-Youn Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Statin-macrolide interaction risk: a population-based study throughout a general practice database.

Authors:  Nadia Piacentini; Gianluca Trifiró; Michele Tari; Salvatore Moretti; Vincenzo Arcoraci
Journal:  Eur J Clin Pharmacol       Date:  2005-07-26       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

9.  Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.

Authors:  I Federico Fernandez Nievas; Kanwaljeet J S Anand
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

10.  Identification of severe potential drug-drug interactions using an Italian general-practitioner database.

Authors:  L Magro; A Conforti; F Del Zotti; R Leone; M L Iorio; I Meneghelli; D Massignani; E Visonà; U Moretti
Journal:  Eur J Clin Pharmacol       Date:  2007-11-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.